Kisqali 600 MG daily dose UU 63S
Ended Awarded Last action
- Contract number
- SPE2DR26FT5TM
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,280
Award facts
- Contract value 100% obligated
- $12,280.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,280 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 28, 2026, for Kisqali 600 mg daily dose tablets (quantity 63 units). The order, which carries an ultimate completion date of February 19, 2026, represents a task order under the company's broader pharmaceutical supply agreement with DLA Troop Support Medical. No set-aside designation was applied to this competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with the work to be performed at its corporate office location in Conshohocken, PA 19428. The company operates as a subsidiary of Cencora, Inc. (UEI: NWEGNLYTBDW4), which holds the parent Indefinite Delivery Contract vehicle valued up to $999,999,999 through December 2031.
This delivery order supports military healthcare operations by supplying Kisqali, a brand-name oncology medication used in cancer treatment protocols. The transaction exemplifies routine pharmaceutical procurement through DLA's established vendor network, enabling efficient delivery of specialized medical commodities to support military treatment facilities and defense healthcare programs. AmerisourceBergen's extensive federal contract portfolio and established relationship with DLA demonstrate the company's critical role in maintaining pharmaceutical supply chain continuity for Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FT5TM?
SPE2DR26FT5TM was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FT5TM worth?
The government has obligated $12,280 on SPE2DR26FT5TM.
Is contract SPE2DR26FT5TM an order under another contract?
Yes. SPE2DR26FT5TM is a delivery order under SPE2DR25D3201, an indefinite delivery contract.
Was contract SPE2DR26FT5TM competed?
The extent of competition for SPE2DR26FT5TM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award